Colorectal adenocarcinoma, with more than 150,000 new cases diagnosed in the United States yearly and approximately 50,000 deaths every year, is a significant public health problem. Despite the emergence of new agents, chemotherapeutic options are of limited efficacy, and novel therapeutic approaches are needed.